The WHO claims estrogens are ‘carcinogenic’: is this true?

References

• WHO-International Agency of Research in Cancer (IARC). Oestrogens and progestins in relation to human cancer. IARC Monogr Eval Carcinog Risk Chem Hum. 1979;21:83–129.
   PubMedGoogle Scholar
• WHO-International Agency of Research in Cancer (IARC). Oestradiol-17 beta, oestradiol 3-benzoate, oestradiol dipropionate, oestradiol-17 beta-valerate and polyoestradiol phosphate. IARC Monogr Eval Carcinog Risk Chem Hum. 1979;21:279–326.
   PubMedGoogle Scholar
• WHO-International Agency of Research in Cancer (IARC). IARC monographs programme finds combined estrogen-progestogen contraceptives and menopausal therapy are carcinogenic to humans. Press Release Nr.167. 29 July 2005.
   Google Scholar
• Cogliano V, Grosse Y, Baan R, et al. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol. 2005;6(8):552–553.
   Google Scholar
• Service RF. Conference of the U.S. National Cancer Institute, Bethesta, March 16–18, 1998. New role of estrogen in cancer. Science. 1998;279(5357):1631–1633.
   PubMed Web of Science ®Google Scholar
• Schneider HPG, Mueck AO, Kuhl H. IARC monographs on carcinogenicity of combined hormonal contraceptives and menopausal therapy (Statement International Menopause Society). Climacteric. 2005;8(4):311–316.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Seeger H. The World Health Organization defines HRT as carcinogenic – is this plausible? Gynecol Endocrinol. 2008;24(3):129–132.
   PubMed Web of Science ®Google Scholar
• Spratt JS, Meyer JS, Spratt JA. Rates of growth of human solid neoplasms: part I. J Surg Oncol. 1995;60(2):137–146.
   PubMed Web of Science ®Google Scholar
• Neubauer H, Adam G, Fehm T, et al. Membrane-initiated effects of progesterone on proliferation and activation of VEGF gene expression in human breast cancer cells. Climacteric. 2009;12(3):230–239.
   PubMed Web of Science ®Google Scholar
• Neubauer H, Ma Q, Zhou J, et al. Possible role of PGRMC1 in breast cancer development. Climacteric. 2013;16(5):509–513.
   PubMed Web of Science ®Google Scholar
• Ruan X, Neubauer H, Yang Y, et al. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells. Climacteric. 2012;15(5):467–472.
   PubMed Web of Science ®Google Scholar
• Ruan X, Gu M, Cai G, et al. Progestogens and PGRMC1-dependent breast cancer tumor growth: an in-vitro and xenograft study. Maturitas. 2019;123:1–8.
   PubMed Web of Science ®Google Scholar
• Ruan X, Zhang Y, Mueck AO, et al. Increased expression of progesterone membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and –negative breast cancer. Menopause. 2017;24(2):203–209.
   PubMed Web of Science ®Google Scholar
• Ruan X, Cai G, Wei Y, et al. Association of circulating Progesterone Receptor Membrane Component-1 (PGRMC1) with breast tumor characteristics and comparison with known tumor markers. Menopause. 2020;27(2):183–193.
   PubMed Web of Science ®Google Scholar
• Cai G, Yang X, Ruan X, et al. Association of circulating Progesterone Receptor Membrane Component-1 (PGRMC1) with PGRMC1 expression in breast tumour tissue and with clinical breast tumour characteristics. Maturitas. 2020;140:64–71.
   PubMed Web of Science ®Google Scholar
• Zhang L, Ruan X, Gu M, et al. Progesterone receptor membrane component 1 (PGRMC1) promotes the PI3K-AKT pathway to induce breast cancer cell proliferation. Climacteric. 2022;25(5):467–475.
   PubMedGoogle Scholar
• Zhao Y, Ruan X, Gu M, et al. PGRMC1 promotes tripe negative breast cancer cell growth via suppressing ferroptosis. Climacteric. 2023;26(2):135–142.
   PubMedGoogle Scholar
• Stanczyk FZ. Can the increase in breast cancer observed in the estrogen plus progestin arm of the Women’s Health Initiative trial be explained by progesterone receptor membrane component 1? Menopause. 2011;18(8):833–834.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291:701–712.
   Web of Science ®Google Scholar
• Spratt JS, Spratt JA. What is breast cancer doing before we can detect it? J Surg Oncol. 1985;30(3):156–160.
   PubMed Web of Science ®Google Scholar
• Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod. 2005;20(8):2052–2060.
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394:1159–1168.
   PubMed Web of Science ®Google Scholar
• Seeger H, Wallwiener D, Mueck AO. Influence of stroma-derived growth factors on the estradiol-stimulated proliferation of human breast cancer cells. Eur J Gynaec Oncology. 2004;25:175–177.
   PubMed Web of Science ®Google Scholar
• Krämer E, Seeger H, Krämer B, et al. The effects of progesterone and synthetic progestogens on growth factor and estradiol treated human cancerous and non-cancerous breast cells. Menopause. 2005;12(4):468–474.
   PubMedGoogle Scholar
• Zhou J, Yu Q, Chen R, et al. Medroxyprogesterone acetate-driven increase in breast cancer risk might be mediated via cross-talk with growth factors in the presence of progesterone receptor membrane component-1. Maturitas. 2013;76(2):129–133.
   PubMed Web of Science ®Google Scholar
• Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis. 2000;21(3):427–433.
   PubMed Web of Science ®Google Scholar
• Ruan X, Mueck AO. Primary choice of estrogen and progestogen as components for HRT – a clinical pharmacological view. Climacteric. 2022;25:443–452.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Seeger H, Wallwiener D. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition. Climacteric. 2003;6(3):221–227.
   PubMed Web of Science ®Google Scholar
• Li X, Ruan X, Gu M, et al. PGRMC1 can trigger estrogen-dependent proliferation of breast cancer cells: estradiol vs. equilin vs. ethinyl-estradiol. Climacteric. 2019;22(5):483–488.
   PubMed Web of Science ®Google Scholar
• Longman SM, Buehring GC. Oral contraceptives and breast cancer. In vitro effect of contraceptive steroids on human mammary cell growth. Cancer. 1987;59(2):281–287.
   PubMed Web of Science ®Google Scholar
• Anderson TJ, Battersby S, King RJB, et al. Oral contraceptive use influences resting breast proliferation. Hum Pathol. 1989;20(12):1139–1144.
   PubMed Web of Science ®Google Scholar
• Seeger H, Lippert C, Wallwiener D, et al. Comparison of the effect of 17alpha-ethinylestradiol and 17ß-estradiol on the proliferation of human breast cancer cells and human umbilical vascular endothelial cells. Clin Exp Obstet Gynecol. 2002;29:87–90.
   PubMedGoogle Scholar
• Cibula D, Gompel A, Mueck AO, et al. Hormonal contraception and risk of cancer. Hum Reprod Update. 2010;16(6):631–650.
   PubMed Web of Science ®Google Scholar
• Schoonen WGEJ, Joosten JWH, Kloosterboer HJ. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines. J Steroid Biochem Mol Biol. 1995;55:423–437.
   PubMed Web of Science ®Google Scholar
• Cappelletti V, Miodini P, Fioravanti L, et al. Effect of progestin treatment on estradiol- and growth factor-stimulated breast cancer cell lines. Anticancer Res. 1995;15:2551–2556.
   PubMed Web of Science ®Google Scholar
• Franke HR, Vermes I. Differential effects of progestagens on breast cancer cell lines. Maturitas. 2003;46:55–58. Suppl1:S55-S58
   PubMed Web of Science ®Google Scholar
• Zhao Y, Ruan X, Wang H, et al. The presence of membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone: a xenograft model. Maturitas. 2017;102:26–33.
   PubMed Web of Science ®Google Scholar
• Seeger H, Mueck AO. HRT and breast cancer caused: caused by progestogens? Experimental vs. clinical data. J Steroid Biochem Mol Biol. 2008;109(1–2):11–15.
   PubMed Web of Science ®Google Scholar
• Chetrite GS, Thole HH, Philippe JC, et al. Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity. Anticancer Res. 2004;24:1433–1438.
   PubMed Web of Science ®Google Scholar
• Ruan X, Mueck AO. Clinical importance of PGRMC1 in hormonal responsive breast cancer. Breast Care. 2022. DOI:10.1159/000527969
   Web of Science ®Google Scholar
• Fournier A, Fabre A, Mesrine S, et al. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptordefined invasive breast cancer. J Clin Oncol. 2008;26(8):1260–1268.
   PubMed Web of Science ®Google Scholar
• Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol. 2009;113(1):65–73.
   PubMed Web of Science ®Google Scholar
• Schneider C, Jick SS, Meier CR. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacteric. 2009;12(6):514–524.
   PubMed Web of Science ®Google Scholar
• Cordina-Duverger E, Truong T, Anger A, et al. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLOS One. 2013;8(11):e78016.
   PubMed Web of Science ®Google Scholar
• Lewis-Wambi JS, Craig Jordan V. Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res. 2009;11(3):206–209.
   PubMed Web of Science ®Google Scholar
• Sweeney EE, Fan P, Jordan VC. Molecular modulation of estrogen induced apoptosis by synthetic progestins in hormone replacement therapy: an insight into the Women’s Health Initiative study. Cancer Res. 2014;74(23):7060–7068.
   PubMed Web of Science ®Google Scholar
• Jordan VC. The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer. 2015;22(1):R1–31.
   PubMed Web of Science ®Google Scholar
• Geske FJ, Gerschenson LE. The biology of apoptosis. Hum Pathol. 2001;32(10):1029–1038.
   PubMed Web of Science ®Google Scholar
• Gompel A, Somai S, Chaouat M, et al. Hormonal regulation of apoptosis in breast cells and tissues. Steroids. 2000;65(10–11):593–598.
   PubMed Web of Science ®Google Scholar
• Hyman B, Muss MD. Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat. 1992;21(1):15–26.
   PubMed Web of Science ®Google Scholar
• Lonning PE, Taylor PD, Anker G, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat. 2001;67(2):111–116.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Seeger H. Invited Editorial: estrogen as a new option for prevention and treatment of breast cancer – does this need a ‘time gap’? Climacteric. 2015;18(4):444–447.
   PubMed Web of Science ®Google Scholar
• Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419–427.
   PubMed Web of Science ®Google Scholar
• Fournier A, Mesrine S, Boutron-Ruault MC, et al. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol. 2009;27(31):5138–5143.
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345(oct09 2):e6409–e6409.
   PubMed Web of Science ®Google Scholar
• Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes on postmenopausal women: results from the women’s health initiative hormone trial. Diabetologica. 2004;47(7):1175–1187.
   PubMed Web of Science ®Google Scholar
• Mester J, Redeuilh G. Proliferation of breast cancer cells: regulation, mediators, targets for therapy. Anticancer Agents Med Chem. 2008;8(8):872–885.
   PubMed Web of Science ®Google Scholar
• Stevenson JC, Farmer RDT. HRT and breast cancer: a million-women study ride again. Climacteric. 2020;23(3):226–228.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Ruan X, Seeger H, et al. Genomic and non-genomic actions of progestogens in the breast. J Steroid Biochem Mol Biol. 2014;142:62–67.
   PubMed Web of Science ®Google Scholar
• Lippert TH, Seeger H, Mueck AO. Estrogens and the cardiovascular system: role of estradiol metabolites in hormone replacement therapy. Climacteric. 1998;1(4):296–301.
   PubMedGoogle Scholar
• Seeger H, Wallwiener D, Kraemer E, et al. Comparison of possible carcinogenic estradiol metabolites: effects on proliferation, apoptosis and metastasis of human breast cancer cells. Maturitas. 2006;54(1):72–77.
   PubMed Web of Science ®Google Scholar
• Liehr JG, Ricci MJ. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci USA. 1996;93(8):3294–3296.
   PubMed Web of Science ®Google Scholar
• Turan VK, Sanchez RI, Li JJ, et al. The effects of steroidal estrogens in ACI rat mammary carcinogenesis: 17ß-estradiol, 2-hydroxyestradiol, 4-hydroxyestradiol, 16a-hydroxyestradiol, and 4-hydroxyestrone. J Endocrinol. 2004;183(1):91–99.
   PubMed Web of Science ®Google Scholar
• Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;354(3):270–282.
   PubMed Web of Science ®Google Scholar
• Kabat GC, O’Leary ES, Gammon MD, et al. Estrogen metabolism and breast cancer. Epidemiology. 2006;17:80–88.
   PubMed Web of Science ®Google Scholar
• Adlercreutz H, Fotsis T, Bannwart C, et al. Urinary estrogen profile determination in young finnish vegetarian and omnivorous women. J Steroid Biochem. 1986;24(1):289–296.
   PubMedGoogle Scholar
• De Crée C, Ball P, Seidlitz B, et al. Plasma 2-hydroxycatecholestrogen responses to acute submaximal and maximal exercise. J Appl Physiol (1985). 1997;82(1):364–370.
   PubMed Web of Science ®Google Scholar
• Liehr JG, Roy D. Free radical generation by redoc cycling of estrogens. Free Radic Biol Med. 1990;8(4):415–423.
   PubMed Web of Science ®Google Scholar
• Abul-Hajj YJ, Tabakovic K, Tabakovic I. An estrogen-nucleic acid adduct. Electroreductive intermolecular coupling of 3,4-estrone o-quinone and adenine. J Am Chem Soc. 1995;117(22):6144–6145.
   Web of Science ®Google Scholar
• Castagnetta LA, Lo Casto M, Granata OM, et al. Estrogen content and metabolism in human breast tumor tissues and cells. Ann N Y Acad Sci. 1996;784:314–324.
   PubMed Web of Science ®Google Scholar
• Rogan EG, Badawi AF, Devanesan PD, et al. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. Carcinogenesis. 2003;24(4):697–702.
   PubMed Web of Science ®Google Scholar
• Chakravarti D, Mailander PC, Li K-M, et al. Evidence that a burst of DNA depurination in sencar mouse skin induces error-prone repair and forms mutations in the H-ras gene. Oncogene. 2001;20(55):7945–7953.
   PubMed Web of Science ®Google Scholar
• Kabat GC, Chang CJ, Sparano JA, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev. 1997;6:505–509.
   PubMed Web of Science ®Google Scholar
• Ursin G, London S, Stanczyk FZ, et al. Urinary 2-hydroxyestrone/16-alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1999;91(12):1067–1072.
   PubMedGoogle Scholar
• Mueck AO, Zimmermann B, Diesing D, et al. Impact of estradiol metabolites on breast cancer risk and factors influencing estradiol metabolism – case control study. J Br Menopause Soc. 2003;9(Suppl(2):31–32.
   Google Scholar
• Lippert TH, Seeger H, Mueck AO. Estradiol metabolism during oral and transdermal estradiol replacement therapy in the postmenopause. Horm Metab Res. 1998;30(9):598–600.
   PubMed Web of Science ®Google Scholar
• Seeger H, Mueck AO, Lippert TH. Effect of norethisterone acetate on estradiol metabolism in postmenopausal women. Horm Metab Res. 2000;32(10):436–439.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Seeger H, Wallwiener D. Impact of hormone replacement therapy on endogenous estradiol metabolism in postmenopausal women. Maturitas. 2002;43(2):87–93.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Seeger H. 2-Methoxyestradiol – biology and mechanism of action. Steroids. 2010;75(10):625–631.
   PubMed Web of Science ®Google Scholar
• Bugano DD, Conforti-Froes N, Yamaguchi NH, et al. Genetic polymorphisms, the metabolism of estrogens and breast cancer: a review. Eur J Gynaecol Oncol. 2008;29:313–320.
   PubMed Web of Science ®Google Scholar
• Ruan X, Mueck AO. Impact of smoking on estrogenic efficacy. Climacteric. 2015;18(1):38–46.
   PubMed Web of Science ®Google Scholar